Now Under FDA Review: Potential First Treatment for Dementia-Related Psychosis
Now under review, the drug pimavanserin may become the first FDA-approved treatment for dementia-related psychosis. Roughly 2.4 million Americans experience symptoms of dementia-related psychosis,…